Triple negative breast cancer: current understanding of biology and treatment options
Triple negative breast cancer: current understanding of biology and treatment options
复制标题
DOI：
10.1097/gco.0b013e3282f40de9
复制
发表时间：
2008-02-01
影响因子：
2.1
通讯作者：
Harris, Lyndsay N.
中科院分区：
文献类型：
--
作者：
Kang, Soonmo Peter;Martel, Maritza;Harris, Lyndsay N.
我们在联合化疗、激素治疗和现代靶向治疗乳腺癌方面取得了显著进展。然而，三阴性乳腺癌的预后很差，而且它们对迄今为止开发的大多数可用的激素或靶向治疗药物不敏感。更好地了解病理生理学、自然史和目前可用的治疗方案对于改善三阴性乳腺癌患者的预后是必要的。最近的发现基因表达谱使我们能够根据不同的基因表达特征将乳腺癌分为五种亚型。这种亚型是预后的，最近的文献表明，这些“分子画像”可能用于预测未来的治疗结果。随着我们为靶向和个体化医学的时代做准备，对三阴性乳腺癌生物学的有限了解对开发新疗法提出了挑战。鉴定更多的分子预测特征及其前瞻性验证将使我们能够更好地表征三阴性乳腺癌并设计最佳治疗方式。
Purpose of reviewWe have made remarkable advances in treatment of breast cancer with combination chemotherapies, hormonal therapies, and modern targeted therapies. Triple negative breast cancers carry a poor prognosis, however, and they are insensitive to most available hormonal or targeted therapeutic agents thus far developed. A better understanding of pathophysiology, natural history, and currently available treatment options is necessary to improve outcomes of patients with triple negative breast cancer.Recent findingsGene expression profiling has allowed us to classify breast cancers into five subtypes based upon distinctive gene expression signatures. This subtyping is prognostic, and the recent literatures suggest that these 'molecular portraits' may be used to predict treatment outcomes in the future.SummaryAs we prepare for an era of targeted and individualized medicine, limited understanding of triple negative breast cancer biology presents a challenge in developing novel therapies. Identification of more molecular predictive signatures and their prospective validation will enable us to characterize triple negative breast cancers better and design optimal treatment modalities.